FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000359780> ?p ?o ?g. }

• W2000359780 endingPage "6079" @default.
• W2000359780 startingPage "6072" @default.
• W2000359780 abstract "Abstract Purpose: More than half of pediatric rhabdomyosarcoma cases have intermediate-risk features and suboptimal outcome (3-year failure-free survival estimates, 55 to 76%). Dose intensification of known active agents may improve outcome. Experimental Design: This pilot study evaluated the feasibility of dose intensification of cyclophosphamide in previously untreated patients ages &lt; 21 years with intermediate-risk rhabdomyosarcoma. Induction therapy comprised four 3-week cycles of VAC: vincristine (V) 1.5 mg/m2 on days 0, 7, and 14; actinomycin D (A) 1.35 mg/m2 on day 0; and dose-intensified cyclophosphamide (C) on days 0, 1, and 2. The three cyclophosphamide dose levels tested were as follows: (a) 1.2 g/m2/dose; (b) 1.5 g/m2/dose; and (c) 1.8 g/m2/dose. Continuation therapy comprised nine additional cycles of VAC with 2.2 g/m2/cycle of C. Radiotherapy was administered at week 0 (parameningeal tumors with intracranial extension) or week 12 or 15 (all others). Results: Between October 1996 and August 1999, 115 eligible patients were enrolled. Three of 15 patients treated at dose level 2 experienced life-threatening dose-limiting toxicity (typhlitis ± other severe toxicity). Dose level 1 was the maximum-tolerated dose, and 91 evaluable patients were treated at this level. The 3-year failure-free and overall survival estimates for patients treated at the maximum-tolerated dose were 52% (95% confidence interval, 41–64%) and 67% (95% confidence interval, 56–77%), respectively, at a median follow-up of 3 years. Conclusions: A 64% increase in the standard cyclophosphamide dosage during induction (to 3.6 g/m2/cycle) was tolerated. However, outcomes were similar to those observed at lower dosages, suggesting that alkylator dose intensification does not benefit patients with intermediate-risk rhabdomyosarcoma." @default.
• W2000359780 created "2016-06-24" @default.
• W2000359780 creator A5014963717 @default.
• W2000359780 creator A5018418303 @default.
• W2000359780 creator A5019589871 @default.
• W2000359780 creator A5028949419 @default.
• W2000359780 creator A5041701143 @default.
• W2000359780 creator A5045312202 @default.
• W2000359780 creator A5059541221 @default.
• W2000359780 creator A5062591516 @default.
• W2000359780 creator A5075735551 @default.
• W2000359780 date "2004-09-15" @default.
• W2000359780 modified "2023-09-26" @default.
• W2000359780 title "Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve Outcome" @default.
• W2000359780 cites W1693048258 @default.
• W2000359780 cites W1703016739 @default.
• W2000359780 cites W1826533514 @default.
• W2000359780 cites W1851609974 @default.
• W2000359780 cites W1888038496 @default.
• W2000359780 cites W1912136430 @default.
• W2000359780 cites W192601499 @default.
• W2000359780 cites W1926287352 @default.
• W2000359780 cites W1980802526 @default.
• W2000359780 cites W1985006583 @default.
• W2000359780 cites W1986157370 @default.
• W2000359780 cites W1995577444 @default.
• W2000359780 cites W2009776028 @default.
• W2000359780 cites W2010711754 @default.
• W2000359780 cites W2015321531 @default.
• W2000359780 cites W2026096307 @default.
• W2000359780 cites W2040408668 @default.
• W2000359780 cites W2071313171 @default.
• W2000359780 cites W2074161946 @default.
• W2000359780 cites W2083616014 @default.
• W2000359780 cites W2089598727 @default.
• W2000359780 cites W2107307464 @default.
• W2000359780 cites W2117823764 @default.
• W2000359780 cites W2123581060 @default.
• W2000359780 cites W2136973158 @default.
• W2000359780 cites W2167270265 @default.
• W2000359780 cites W2207262939 @default.
• W2000359780 cites W2225890143 @default.
• W2000359780 cites W2257281028 @default.
• W2000359780 cites W2267126688 @default.
• W2000359780 cites W2317779966 @default.
• W2000359780 doi "https://doi.org/10.1158/1078-0432.ccr-04-0654" @default.
• W2000359780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15447992" @default.
• W2000359780 hasPublicationYear "2004" @default.
• W2000359780 type Work @default.
• W2000359780 sameAs 2000359780 @default.
• W2000359780 citedByCount "53" @default.
• W2000359780 countsByYear W20003597802012 @default.
• W2000359780 countsByYear W20003597802013 @default.
• W2000359780 countsByYear W20003597802014 @default.
• W2000359780 countsByYear W20003597802015 @default.
• W2000359780 countsByYear W20003597802016 @default.
• W2000359780 countsByYear W20003597802017 @default.
• W2000359780 countsByYear W20003597802018 @default.
• W2000359780 countsByYear W20003597802019 @default.
• W2000359780 countsByYear W20003597802020 @default.
• W2000359780 countsByYear W20003597802021 @default.
• W2000359780 countsByYear W20003597802022 @default.
• W2000359780 crossrefType "journal-article" @default.
• W2000359780 hasAuthorship W2000359780A5014963717 @default.
• W2000359780 hasAuthorship W2000359780A5018418303 @default.
• W2000359780 hasAuthorship W2000359780A5019589871 @default.
• W2000359780 hasAuthorship W2000359780A5028949419 @default.
• W2000359780 hasAuthorship W2000359780A5041701143 @default.
• W2000359780 hasAuthorship W2000359780A5045312202 @default.
• W2000359780 hasAuthorship W2000359780A5059541221 @default.
• W2000359780 hasAuthorship W2000359780A5062591516 @default.
• W2000359780 hasAuthorship W2000359780A5075735551 @default.
• W2000359780 hasBestOaLocation W20003597801 @default.
• W2000359780 hasConcept C126322002 @default.
• W2000359780 hasConcept C141071460 @default.
• W2000359780 hasConcept C142724271 @default.
• W2000359780 hasConcept C2776694085 @default.
• W2000359780 hasConcept C2776755627 @default.
• W2000359780 hasConcept C2778256501 @default.
• W2000359780 hasConcept C2779429289 @default.
• W2000359780 hasConcept C2780844630 @default.
• W2000359780 hasConcept C29730261 @default.
• W2000359780 hasConcept C44249647 @default.
• W2000359780 hasConcept C509974204 @default.
• W2000359780 hasConcept C71924100 @default.
• W2000359780 hasConcept C90924648 @default.
• W2000359780 hasConceptScore W2000359780C126322002 @default.
• W2000359780 hasConceptScore W2000359780C141071460 @default.
• W2000359780 hasConceptScore W2000359780C142724271 @default.
• W2000359780 hasConceptScore W2000359780C2776694085 @default.
• W2000359780 hasConceptScore W2000359780C2776755627 @default.
• W2000359780 hasConceptScore W2000359780C2778256501 @default.
• W2000359780 hasConceptScore W2000359780C2779429289 @default.
• W2000359780 hasConceptScore W2000359780C2780844630 @default.
• W2000359780 hasConceptScore W2000359780C29730261 @default.
• W2000359780 hasConceptScore W2000359780C44249647 @default.
• W2000359780 hasConceptScore W2000359780C509974204 @default.
• W2000359780 hasConceptScore W2000359780C71924100 @default.

• next